参考文献
[1] Baik C S, WuD, Smith C, et al. Durable Responseto Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient HarboringEpidermal Growth Factor Receptor Tandem Kinase Domain Duplication[J]. J ThoracOncol, 2015, 10(10): e97-9.
[2] Gallant J N, SheehanJ H, Shaver T M, et al. EGFR KinaseDomain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer ThatIs Clinically Responsive to Afatinib[J]. Cancer Discov, 2015, 5(11): 1155-63.
[3] Costa D B. Kinaseinhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: movingpast common point mutations or indels into uncommon kinase domain duplicationsand rearrangements[J]. Transl Lung Cancer Res, 2016, 5(3): 331-7.
[4] Castellanos E,Feld E, Horn L. Driven by Mutations: The Predictive Value of Mutation Subtypein EGFR-Mutated Non-Small Cell Lung Cancer[J]. J Thorac Oncol, 2016, [Epubahead of print].